Fig. 3
From: New opportunities for RGD-engineered metal nanoparticles in cancer
In vivo targeting with RGD-modified indium-111 labeled gold nanoparticles. Biodistribution studies were performed in M21, M21-L and U87 tumor xenografts. The organ (A) and tumor biodistribution (B) demonstrated higher tumor uptake with RGD modified indium-111 labeled gold nanoparticles when compared with the non-targeted nanoparticles in the U87 tumor model. SPECT/CT imaging (C) demonstrated higher uptake of RGD-modified indium-111 labeled gold nanoparticles in the M21 tumor (left) compared to the M21-L tumor (right). Reproduced with permission from ref [93]